Effect of remdesivir on mortality rate and clinical status of COVID-19 patients: a systematic review with meta-analysis

Review Pharmacology & Pharmacy

Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials

Driton Vela et al.

Summary: Tocilizumab has shown efficacy and safety in treating patients with COVID-19. Its use reduces all-cause mortality and the risk of progression to mechanical ventilation without increasing serious adverse events.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

R. L. Gottlieb et al.

Summary: In symptomatic, nonhospitalized high-risk Covid-19 patients, a 3-day course of remdesivir significantly reduced the risk of hospitalization or death compared to placebo, with acceptable safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Medicine, General & Internal

Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points

Anjum S. Kaka et al.

Summary: This review updates the evidence on the use of Remdesivir for adult patients with COVID-19. The findings suggest that Remdesivir may not significantly reduce mortality but increases the proportion of recovered patients. It may reduce time to clinical improvement and decrease serious adverse events, but may increase any adverse events.

ANNALS OF INTERNAL MEDICINE (2022)

Add to Collection

Review Pharmacology & Pharmacy

An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19)

Pasquale Pagliano et al.

Summary: Remdesivir is a widely investigated antiviral drug for treating COVID-19, showing promising activity against SARS-CoV-2 in vitro studies by suppressing viral replication. However, its efficacy in reducing mortality has not been clearly demonstrated.

EXPERT OPINION ON DRUG DISCOVERY (2022)

Add to Collection

Article Medicine, General & Internal

Adverse Events Associated with BNT162b2 and AZD1222 Vaccines in the Real World: Surveillance Report in a Single Italian Vaccine Center

Maria Costantino et al.

Summary: This observational study reports potential adverse events following immunization with two different COVID-19 vaccines, AZD1222 and BNT162b2. The study found a higher incidence of adverse events in the AZD-vac group compared to the BNT-vac group. Fever was the most frequent adverse event associated with AZD1222, while pain at the injection site was most frequent with BNT162b2. The study also found a higher incidence of adverse events in women after receiving the BNT162b2 vaccine.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Immunology

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

Susan A. Olender et al.

Summary: In a comparative analysis, remdesivir was found to be associated with significantly higher recovery rates and a 62% reduced mortality rate compared to standard-of-care treatment by day 14 in patients with severe COVID-19.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A. C. Kalil et al.

Summary: Combination treatment with baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Infectious Diseases

Characteristics of viral pneumonia in the COVID-19 era: an update

P. Pagliano et al.

Summary: Viral pneumonia caused by influenza virus, rhinovirus, adenovirus, and coronavirus is a significant cause of community-acquired pneumonia, particularly in extreme age groups. Severe cases can result in respiratory failure, with the elderly and cancer patients being at higher risk of adverse outcomes.

INFECTION (2021)

Add to Collection

Article Immunology

Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study

Thomas Benfield et al.

Summary: The study found that treatment with remdesivir and dexamethasone for moderate to severe COVID-19 between June and December was associated with reduced 30-day mortality and need for mechanical ventilation compared to treatment between February and May.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection

Yu Ling Tan et al.

Summary: The study found that remdesivir monotherapy significantly inhibited live virus and viral RNA replication, while ivermectin treatment showed the highest selectivity index. Combination drug therapy exhibited strong synergistic effects, especially the combination of remdesivir and ivermectin showed the most significant reduction in live virus and viral RNA in infected macrophages.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience

Alessandro Russo et al.

Summary: The study results suggest that the use of remdesivir in hospitalized patients with COVID-19 was not significantly associated with increased survival rates or reduced need for high-flow oxygen therapy and mechanical ventilation.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Review Health Care Sciences & Services

Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis

Valeria Conti et al.

Summary: The meta-analysis suggests that Tocilizumab may reduce mortality in COVID-19 patients. While observational studies showed a significant reduction in mortality with Tocilizumab, there was no similar effect found in RCTs. Personalizing therapy based on patient characteristics is essential.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection

Letter Cell Biology